Table 5

Meibomian gland parameters in group 1

Drug classCell density of eyelid margin, cells/mm2Acinar unit
Superficial epitheliumBasal epitheliumArea, µm2±SDDensity, units/mm2Secretion reflectivityGlandular orifice area, µm2±SDMG wall:inhomogeneous appearance of MG wallPeriglandular interstice:inhomogeneous appearance of MG interstice
Controls1810.27±234.194066.94±284.5417020.49±7284.38*219.31±50.62*1.12±0.22**1894.44±336.65*** 1.33±0.37****1.11±0.25****
Preserved β-blockers1759.50±135.43926.16±451.6415737.66±1752.99222.94±72.551.14±0.261784.08±143.241.65±0.41.32±0.44
PF β-blockers1850.50±245.24089.75±113.3716503.08±3555.54218.65±21.861.07±0.161807.9±331.81.19±0.331.17±0.23
Preserved PGA1743.07±157.273840.23±238.3714283.51±3226.05***152.84±37.97*****1.40±0.36***1988.08±908.541.99±0.36***2.11±0.68***
PF-PGA1903.75±96.004001.37±121.5618362.59±5886.26224.28±54.78*1.09±0.131930.53±1041.521.33±0.461.38±0.34
  • *p<0.05 vs preserved PGA.

  • **p<0.02 vs preserved PGA.

  • ***p<0.05 vs PF-PGA.

  • ****p<0.05 vs preserved PGA.

  • *****p<0.05 vs preserved β-blockers.

  • MG, Meibomian gland; PF, preservative free; PF-β-blockers, preservative-free timolol 0.5%; PF-PGA, preservative-free tafluporst; PGA, prostaglandin analogue; preserved β-blockers, timolol 0.5%; preserved PGA, preserved latanoprost.